The US Food and Drug Administration has approved Krystal Biotech’s Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB). It is approved for treating wounds in patients six months of age and older with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. “Vyjuvek […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!